Kisqali-Endocrine Therapy Combo Increases Overall Survival In Hormone Receptor-Positive Breast Cancer Patients, Study Shows

Kisqali-Endocrine Therapy Combo Increases Overall Survival In Hormone Receptor-Positive Breast Cancer Patients, Study Shows
A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive breast cancer, a Phase 3 clinical trial suggests. Findings from the MONALEESA-7 trial (NCT02278120) were presented during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in the late-breaking presentation, "Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results." They were published simultaneously in The New England Journal of Medicine. Kisqali is a targeted therapy developed by Novartis. It blocks the activity of cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6. CDKs are proteins that help control the process of cell division; in the case of cancer, these proteins can spur tumor growth. "Kisqali has characte
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.